The Medical Letter on Drugs and Therapeutics
Opill — An OTC Oral Contraceptive
September 18, 2023 (Issue: 1685)The FDA has approved Opill (Perrigo), a progestin-only oral contraceptive that contains norgestrel, for sale over the counter (OTC). Opill is the first oral contraceptive to be approved in the US for sale without a prescription. Approval of OTC...more
- FDA News Release. FDA approves fi rst nonprescription daily oral contraceptive. July 13, 2023. Available at: https://bit.ly/45chDlt. Accessed August 29, 2023.
- Choice of contraceptives. Med Lett Drugs Ther 2023; 65:73.
- EY Adashi et al. The FDA declares levonorgestrel a nonabortifacient — a 50-year saga takes a decisive turn. JAMA Health Forum 2023; 4:e232257. doi:10.1001/jamahealthforum.2023.2257
- C Zuniga et al. Effectiveness and effi cacy rates of progestin-only pills: a comprehensive literature review. Contraception 2023; 119:109925. doi:10.1016/j.contraception.2022.109925
- FDA. Opill (0.075mg oral norgestrel tablet) information. July 14, 2023. https://bit.ly/4532a6S. Accessed August 29, 2023.
- A Glasier et al. A review of the effectiveness of a progestogen-only pill containing norgestrel 75 μg/day. Contraception 2021; 105:1. doi:10.1016/j.contraception.2021.08.016
- KM Murray. FDA decisional memorandum. New drug application 17031 supplement 41. Application for full prescription-to-nonprescription switch of norgestrel tablets 0.075 mg. Available at: https://bit.ly/3OYyKAG. Accessed August 29, 2023.
- D Fitzpatrick et al. Combined and progestagen-only hormonal contraceptives and breast cancer risk: a UK nested case-control study and meta-analysis. PLoS Med 2023; 20:e1004188. doi:10.1371/journal.pmed.1004188
- JN Hultstrand et al. Hormonal contraception and risk of breast cancer and breast cancer in situ among Swedish women 15-34 years of age: a nationwide register-based study. Lancet Reg Health Eur 2022; 21:100470. doi:10.1016/j.lanepe.2022.100470
- KB Simmons et al. Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic review. Am J Obstet Gynecol 2018; 218:88. doi:10.1016/j.ajog.2017.07.003
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.